About Us

Vision & Mission

We envision a future shaped by AI4S — AI for Science — where RNA drug discovery moves at the speed of thought, empowering every researcher to turn an idea into a validated therapeutic candidate faster than ever before.

Our mission is to build closed-loop, AI-agent platforms like KumiChem™ that automate the RNA and oligonucleotide drug discovery workflow — from target identification to lead optimization — so breakthroughs reach patients sooner.

Culture

At the heart of our culture is a belief in the uniqueness of every team member. We create an environment that values individual strengths and skills, helping each person unlock their potential and make a meaningful impact.

Open feedback, support, and celebrating achievements together foster an atmosphere where personal and team growth go hand in hand.

We inspire one another with fresh ideas, learn together, mark important milestones, and move forward every day—toward innovation, excellence, and shared success

Introducing our team

The people building DLeader's AI-driven drug discovery platform.

DR. QINGWEN CHEN
DR. QINGWEN CHEN
Founder & CEO
During my AI X chemistry doctorate at Osaka University, a collaboration in information science sparked a vision: to transform drug discovery through AI. I founded DLeader to realize that vision by building a Closed-Loop Automatic AI Drug Discovery Platform.
Our mission is to create generative tools that support and accelerate AI-driven drug discovery (AIDD), empowering researchers with smarter, faster, and more collaborative innovation.
At DLeader, we strive to make advanced pharmaceutical research more efficient, accessible, and impactful for all.
MINGXIN ZHANG, MS (TOM)
MINGXIN ZHANG, MS (TOM)
Co-founder & CTO/CAIO
I believe AI4S (AI for Science) is the next major innovation that can push AI performance to new heights and revolutionize industries, particularly in drug discovery and cheminformatics.
I am passionate about this challenge because I'm convinced AI4S will spark the next wave of transformative progress in science and technology.
MIZUKI YASUDA
MIZUKI YASUDA
Advisor
Graduate of Meiji University's School of Agriculture and a certified public accountant. Founded and successfully exited a plant factory startup. Currently in Friends Co., Ltd., engaged in product development support and investment ventures.
Joined DLeader upon resonating with the vision of founder Chen is a former intern at Friends, corp., and executed an investment to ensure the growth and success of DLeader.
I am dedicated to driving business growth in all aspects, including talent acquisition, funding, and product development.
Dr. Mizuguchi Kenji
Dr. Mizuguchi Kenji
Scientific Advisorprof. at the University of Osaka
Prof. Mizuguchi leads research that integrates informatics and computational chemistry to uncover the mechanisms of diseases and apply findings to drug discovery. His lab focuses on integrating diverse biological data—from genes and proteins to diseases and compounds—to power AI-driven analysis.
He also develops predictive models for protein structure, function, and interactions, with applications in fields like immunology and developmental biology, as well as early-stage drug profiling.
Link to Mizuguchi Lab
Dr. Nakatani Kazuhiko
Dr. Nakatani Kazuhiko
Scientific AdvisorEmeritus prof. at the University of Osaka
Prof. Kazuhiko Nakatani is a leading expert in developing small molecules that target nucleic acids, focusing on those that recognize mismatched base pairs in triplet repeat sequences implicated in neurodegenerative diseases.
Recently, Nakatani group explore AI and computer-aided approaches in drug discovery research, advancing the design of novel therapeutic candidates.
Link to Nakatani Lab
Dr. Yamada Takeshi
Dr. Yamada Takeshi
Scientific AdvisorJunior Associate Prof., Institute of Science Tokyo
Dr. Yamada Takeshi is a specialist in synthetic organic chemistry, chemical biology, and nucleic-acid drug development, serving as a lecturer at the Nucleotide and Peptide Drug Discovery Center (TIDE), Tokyo University of Science. His research focuses on designing antisense oligonucleotides (ASOs) and heteroduplex oligonucleotides (HDOs), particularly improving drug-delivery systems and pharmacokinetics to advance nucleic-acid therapeutics. He aims to contribute to next-generation treatments for challenging diseases through innovative oligonucleotide-based drugs.
Recently, Nakatani group explore AI and computer-aided approaches in drug discovery research, advancing the design of novel therapeutic candidates.
Link to Yamada Takeshi

Stay one step ahead and accelerate your research

Person icon
Person icon
Company icon
Position icon
Email icon
Comment icon
DLeader Logo

DLeader Inc

Your powerful AI agent
drug discovery tool

Company Name: DLeader株式会社 / DLeader, Inc.
CEO: QINGWEN CHEN
Location: 12-12, Osaka Ekimae No. 2 Building, 2-2
Umeda 1-chome, Kita-ku, Osaka City, Osaka
Date Founded : April, 12, 2024
Capital: 10 million JPY
TopPlatform
CompanyContact

© 2026 DLeader, Inc. All rights reserved.

About Us | DLeader Inc.